NCT04304040 - A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

B-cell Lymphoma RecurrentB-cell Lymphoma Refractory

Interventions

DRUG

Orelabrutinib

BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

DRUG

Recombinant humanized monoclonal antibody MIL62 injection

Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

Trial Locations (10)

100000

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Beijing Hospital, Beijing

Beijing Shijitan hospital, capital medical university, Beijing

Cancer hospital, Chinese academy of medical sciences, Beijing

Affiliated Hospital of Hebei University, Baoding

Henan Tumor Hospital, Zhengzhou

Hunan Cancer Hospital, Changsha

First Affiliated Hospital of Soochow University, Suzhou

The First Hospital of Jilin University, Changchun

Tianjin People's Hospital, Tianjin

All Listed Sponsors

lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY